Deals channel feed

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Last year
Financing
Startups

Gen­mab fu­els AD­C­s' hot streak with $1.8B buy­out of Pro­found­Bio

Last year

Acor­da files for bank­rupt­cy, agrees to sell MS drug and oth­er as­sets to Merz for $185M

Last year
Pharma

Ipsen boards ADC train in $900M pact with Sutro

Last year
Pharma

Roivant an­nounces study win in eye dis­ease for Pfiz­er as­set, plans $1.5B share buy­back

Last year
R&D

Car­lyle’s Abing­worth will help fund Te­va’s Phase 3 asth­ma res­cue in­haler

Last year
R&D
Pharma

Gilead pays $43M to li­cense Xilio’s IL-12 pro­gram that could turn ‘cold’ tu­mors ‘hot’

Last year

Up­dat­ed: Mod­er­na part­ners with Black­stone on flu shots, nab­bing up to $750M in R&D fund­ing

Last year
Financing
R&D

In small ac­qui­si­tion, Ab­b­Vie adds Lan­dos and its IBD drug to post-Hu­mi­ra plans

Last year
R&D

Nu­va­tion inks all-stock deal for US-Chi­na on­col­o­gy biotech An­Heart

Last year
Startups
China

No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

Last year
Startups
Pharma

As­traZeneca views $2B+ Fu­sion buy­out as ‘start­ing point’ for bet­ter ra­dio­phar­ma­ceu­ti­cals, com­bos

Last year
Pharma

As­traZeneca snaps up ra­dio­phar­ma part­ner for $2B up­front

Last year

Mer­ck’s six-year deal strat­e­gy could de­liv­er a block­buster if hy­per­ten­sion drug is OK’d this month

Last year

Pfiz­er sells off par­tial stake in Ha­le­on, po­ten­tial­ly rais­ing $2B+

Last year
Pharma

As­traZeneca eyes rare en­docrinol­o­gy mar­ket with $1.05B buy­out of Amolyt Phar­ma

Last year
R&D

WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

Last year
China
In Focus

Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Last year
R&D

No­var­tis re­turns for an­oth­er piece of IFM Ther­a­peu­tics

Last year
Pharma

Mer­ck pens pact with Pearl Bio for new bi­o­log­ics in can­cer

Last year
Startups
Pharma

Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Last year
China
In Focus

Boehringer In­gel­heim inks deal for So­sei’s GPR52-tar­get­ing schiz­o­phre­nia port­fo­lio

Last year

Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Last year
R&D

Mer­ck KGaA to fo­cus on ‘ex­ter­nal in­no­va­tion’ as it ex­its BTK in­hibitor race

Last year
R&D
First page Previous page 17181920212223 Next page Last page
A service from the Financial Times